Koji Hasegawa

Koji Hasegawa

Director, Division of Translational Research

National Hospital Organization Kyoto Medical Center, Fushimi-ku, Kyoto, Japan

  • Radcliffe

Biography

Director, Division of Translational Research, Kyoto Medical Center
Leader, Cardiovascular Clinical Research Network, National Hospital Organization
Visiting Professor, University of Shizuoka
Past President, International Society of Cardiovascular Pharmacotherapy (2018)

 

 

Reasearch areas

Obesity

Articles

A Multicentre, Open-Label, Randomised Controlled Clinical Trial to Assess the Efficacy and Safety of Appropriate Target Values for Lipid Management in Patients who Have Mild to Moderate Stenotic Lesions with High-Risk Plaques in Coronary Arteries

Morihiro Matsuda, Koji Hasegawa,

Published:

Citation: European Cardiology Review 2020;15:e47.

Dilated Cardiomyopathy Risk in Patients with Coronavirus Disease 2019: How to Identify and Characterise it Early?

Maki Komiyama, Koji Hasegawa, Akira Matsumori,

Published:

Citation: European Cardiology Review 2020;15:e49.

Response to the Comment ‘Smoking and Angiotensin-converting Enzyme Inhibitor/Angiotensin Receptor Blocker Cessation to Limit Coronavirus Disease 2019’

Maki Komiyama, Koji Hasegawa,

Published:

Citation: European Cardiology Review 2020;15:e55.

Anticoagulant Therapy for Patients with Coronavirus Disease 2019: Urgent Need for Enhanced Awareness

Maki Komiyama, Koji Hasegawa,

Published:

Citation: European Cardiology Review 2020;15:e58.

Applications for Induced Pluripotent Stem Cells in Disease Modelling and Drug Development for Heart Diseases

Shu Nakao, Dai Ihara, Koji Hasegawa,

Published:

Citation: European Cardiology Review 2020;15:e02.

Smoking Cessation as a Public Health Measure to Limit the Coronavirus Disease 2019 Pandemic

Maki Komiyama, Koji Hasegawa,

Published:

Citation: European Cardiology Review 2020;15:e16.

Obesity and Cardiovascular Risk After Quitting Smoking: The Latest Evidence

Koji Hasegawa, Maki Komiyama, Yuko Takahashi,

Published:

Citation: European Cardiology Review 2019;14(1):60–1

Anti-inflammatory Action of Curcumin and Its Use in the Treatment of Lifestyle-related Diseases

Kana Shimizu, Masafumi Funamoto, Yoichi Sunagawa,

Published:

Citation: European Cardiology Review 2019;14(2):117–22

Analysis of the Effects of EPA and DHA on Cardiomyocyte hypertrophy

Ayumi Katayama, Masafumi Funamoto, Kana Shimizu,

Citation: European Cardiology Review 2018;13(2):121.

Relationship Between VEGF-C Levels and Mortality in Patients with Peripheral Artery Disease

Nobutoyo Masunaga, Shuichi Ura, Mitsuru Ishii,

Citation: European Cardiology Review 2018;13(2):123.

VEGF-C and Cardiovascular Mortality in Patients Undergoing Drug-eluting Stent Implantation

Takashi Unoki, Shuichi Ura, Daisuke Takagi,

Citation: European Cardiology Review 2018;13(2):124.

The GATA4 Acetylation Site Plays a Key Role in the Development of Cardiomyocyte Hypertrophy

Satoshi Shimizu, Yoichi Sunagawa, Kodai Hara,

Citation: European Cardiology Review 2018;13(2):125.

TBL1 Suppresses Cardiomyocyte Hypertrophy by Regulating the Interaction Between HDAC3 and GATA4

Yasufumi Katanasaka, Masatoshi Namiki, Yoichi Sunagawa,

Citation: European Cardiology Review 2018;13(2):126.

Relationship Between VEGF-C Levels and All-cause Mortality in Patients with Chronic Heart Failure

Moritake Iguchi, Shuichi Ura, Nobutoyo Masunaga,

Citation: European Cardiology Review 2018;13(2):129.

A PRMT5 Selective Inhibitor EPZ015666 Suppressed TAC-induced Left Ventricular Dysfunction

Kazuma Hanajima, Yusuke Miyazaki, Yasufumi Katanasaka,

Citation: European Cardiology Review 2018;13(2):130.

Erratum to: The Inhibitory Effects of Crucumin Glucuronide on p300-HAT Activity and Hypertrophic Phenylephrine- Induced Responses in Cardiomyocytes

Mai Genpei, Yoichi Sunagawa, Masafumi Funamoto,

Citation: European Cardiology Review 2018;13(2):136.

23rd Annual Scientific Meeting of the International Society of Cardiovascular Pharmacotherapy

Koji Hasegawa,

Citation: European Cardiology Review 2018;13(2):119

ISCP Guest Editorial: Cardiovascular Disease Prevention in Diabetes

Maki Komiyama, Koji Hasegawa,

Citation: European Cardiology Review 2018;13(1):21–2.

Cardiovascular Risk Management Targeting Inflammation in Addition to Lipid-lowering Therapy

Koji Hasegawa,

Citation: European Cardiology Review 2017;12(2):88

Nobiletin a Citrus Flavonoid, Exerts Additional Effects with Angiotensin II Receptor Blocker on Systolic Function in Salt-sensitive Dahl Rats

Haruka Ebi, Masafumi Funamoto, Yoichi Sunagawa,

Citation: European Cardiology Review 2017;12(2):92.

Effects of Pharmacotherapy for Smoking Cessation on LOX Index, a Cardiovascular Risk Marker

Maki Komiyama, Hiromichi Wada, Hajime Yamakage,

Citation: European Cardiology Review 2017;12(2):96.

A Novel Target Molecule of Nobiletin Derived from Citrus Peels has a Therapeutic Potency Against the Development of Heart Failure

Yoichi Sunagawa, Masafumi Funamoto, Anna Suzuki,

Citation: European Cardiology Review 2017;12(2):105.

Curcumin Analogue GO-Y030 Significantly Improves Pressure Overload-induced Heart Failure in Vivo

Kana Shimizu, Masafumi Funamoto, Mai Genpei,

Citation: European Cardiology Review 2017;12(2):106.

The Inhibitory Effects of Curcumin Glucuronide on p300-HAT Activity and Hypertrophic Phenylephrine-Induced Responses in Cardiomyocytes

Mai Genpei, Yoichi Sunagawa, Masafumi Funamoto,

Citation: European Cardiology Review 2017;12(2):107.

A Transcriptional Co-activator, p300 is Involved in the Epigenetic Gene Activation on Hypertrophic Response Gene Promoters in Heart Failure

Masafumi Funamoto, Yoichi Sunagawa, Yasufumi Katanasaka,

Citation: European Cardiology Review 2017;12(2):110.

Analysis of Factors Associated with Smoking Relapse

Sayaka Shimada, Maki Komiyama, Hiromichi Wada,

Citation: European Cardiology Review 2017;12(2):111.